PROALT has been selected by the European Innovation Council (EIC) to pitch its innovative therapeutic solutions in oncology to top European investors at the EIC Investor Day with CUF. The event took place in Lisbon (Portugal) on 29 and 30 November 2022, where the Company has presented in the ‘Biotech & Pharmaceuticals session’ its antibodies targeting CDH17 and IL13Ra2 aimed at treating metastatic colorectal cancer and glioblastoma.
EIC-funded companies were selected by an exclusive investor jury from top European VCs & CVCs with notable investments in the healthcare sector. PROALT has presented its innovative approaches in front of top European investors during the session #1 ‘Biotech & Pharmaceuticals’ and meet them in private one-to-one meetings.
CUF is the market leader in the healthcare sector in Portugal with 77 years of experience and more than 11.000 employees. It is part of José de Mello SGPS, an economic group that operates in several strategic sectors in the country. The CUF network develops its activity through 20 healthcare units: ten hospitals, nine clinics, one institute, and is present in thirteen municipalities, with a potential for coverage of almost six million portuguese. Innovation is also part of CUF’s DNA. CUF is teaming up with the EIC to bring an Investor Day to EIC innovators working on solutions in the areas of Medtech, E-Health and Biotech & Pharmaceuticals.